



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
John R. Erbey II, et al.

Serial No.: 10/700,909

Filed: 08/07/2003

For: Methods and Therapeutic
Combinations for the Treatment
Of Autoimmune Disorders

Examiner: To Be Assigned

Group Art Unit: 1614

Atty. Docket No.: CV06093

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references are attached were filed in related application U.S. Serial No(s) _____ filed _____, respectively.

(b) No fee is believed due because:

- This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- This Information Disclosure Statement is being concurrently filed with the above-identified application.
- This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

- The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- (d) This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365, Patent Case No. CV06093.

Respectfully submitted,
SCHERING-PLOUGH CORPORATION

Dated: April 19, 2004
SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

By:


Name: Ann M. Cannon
Reg. No.: 35,972
Attorney of Record
Telephone No.: (908) 298-5024

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450 ON April 19, 2004
ANN MARIE CANNONI, REG. NO. 35,972
(DATE OF DEPOSIT) (REGISTERED REPRESENTATIVE)


(SIGNATURE AND DATE)



Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV06093	APPLICATION NO.: 10/700,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT: John R. Erbey II, et al.	
(Use several sheets if necessary)		FILING DATE: 08/07/2003	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AL						
AM						
AN						
AO						
AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	T. Kosoglou <i>et al.</i> , "CoAdministration of Simvastatin and Ezetimibe Leads to Significant Reduction in LDL-Cholesterol", Proceedings of 3 rd International Congress on Coronary, Artery Disease from Prevention to Intervention, Lyon, France p. 271 (2000), XP008027568
AR	
AS	
AT	
AU	
AV	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.